Abstract
1 Propyphenazone 220 mg was administered orally to volunteers. Maximum plasma concentrations between 1.5 μg/ml and 3.5 μg/ml were found 30 min later. After comparable doses plasma concentrations in dog and rabbit were lower. The distribution volumes were 2 1/kg.
2 The major metabolic route of propyphenazone is demethylation. The main urinary metabolite is the enolglucuronide of N-(2)-demethylprophyphenazone.
3 Aminopyrine is rapidly and almost completely absorbed after oral administration. Maximum plasma concentrations of 10 μg/ml are reached 1.5 h after a 500 mg dose. The biological half-life is 2-3 h, the relative distribution volume 60% on average, and binding to plasma proteins approximately 15%.
4 Unchanged aminopyrine is only excreted in small quantities. The major routes of metabolism are demethylation (4-methylaminoantipyrine and 4-aminoantipyrine) and acylation (4-acetyl and 4-formylaminoantipyrine). There are other biotransformation products.
5 After oral administration of [14C]-dipyrone 480 mg the maximum serum concentration of 13.4±0.8 μg/ml occurred at 1-1.5 hours.
6 Dipyrone was not detectable in serum or urine. Four of seven metabolites were identified, and were identical with the main metabolites of aminopyrine.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anania V., Borroni G., Catanese B. Ricerche comparative sull'assorbimento del paracetamolo e dell'aminofenazone nell'uomo dopo somministrazione per via orale o rettale. Boll Chim Farm. 1976 Oct;115(10):726–731. [PubMed] [Google Scholar]
- BRODIE B. B., AXELROD J. The fate of aminopyrine (pyramidon) in man and methods for the estimation of aminopyrine and its metabolites in biological material. J Pharmacol Exp Ther. 1950 Jun;99(2):171–184. [PubMed] [Google Scholar]
- Christ O., Kellner H. M., Ross G., Rupp W., Schwarz A. [Biopharmaceutical and pharmacokinetic studies on metamizol-14C (Novalgin 14C) given to rats, dogs and men]. Arzneimittelforschung. 1973 Dec;23(12):1760–1767. [PubMed] [Google Scholar]
- Eisenbrand G., Spiegelhalder B., Kann J., Klein R., Preussmann R. Carcinogenic N-nitrosodimethylamine as a contamination in drugs containing 4-dimethylamino-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one (amidopyrine, aminophenazone). Arzneimittelforschung. 1979;29(6):867–869. doi: 10.1002/chin.197938327. [DOI] [PubMed] [Google Scholar]
- Fleischmann L. Aminopyrin-Resorption und -Stoffwechsel nach rektaler Verabreichung beim Menschen. Pharm Acta Helv. 1973 Apr;48(4):192–199. [PubMed] [Google Scholar]
- Gradnik R., Fleischmann L. Quantitative Harnausscheidung verschiedener Aminopyrin-Stoffwechselprodukte beim Menschen. Pharm Acta Helv. 1973 Apr;48(4):181–191. [PubMed] [Google Scholar]
- HALBERKANN J., FRETWURST F. Die Stoffwechselprodukte des Pyramidons und verwandter Verbindungen beim Menschen. Hoppe Seylers Z Physiol Chem. 1950 Mar;285(1-3):97–127. doi: 10.1515/bchm2.1950.285.1-3.97. [DOI] [PubMed] [Google Scholar]
- Iguchi S., Goromaru T., Noda A. Communications to the editor: A new metabolite of aminopyrine (aminophenazone) in man, 4-formylaminoantipyrine. Chem Pharm Bull (Tokyo) 1975 Apr;23(4):932–934. doi: 10.1248/cpb.23.932. [DOI] [PubMed] [Google Scholar]
- Jori A., Di Salle E., Quadri A. Rate of aminopyrine disappearance from plasma in young and aged humans. Pharmacology. 1972;8(4):273–279. doi: 10.1159/000136343. [DOI] [PubMed] [Google Scholar]
- Klinger W. Zur Pharmakokinetik von Dimethylaminophenazon, 4-Aminophenazon und Phenazon bei Ratten verschiedenen Alters. Arch Int Pharmacodyn Ther. 1969 Aug;180(2):309–322. [PubMed] [Google Scholar]
- Koizumi T., Ueda M., Takada S. Urine data analysis for pharmacokinetics of aminopyrine and its metabolites in man. Chem Pharm Bull (Tokyo) 1974 Apr;22(4):894–906. doi: 10.1248/cpb.22.894. [DOI] [PubMed] [Google Scholar]
- Lavene D., Longchampt J., Guillaume M. F., Kiger J. L. Drug interactions of the components of Optalidon after oral administration. Int J Clin Pharmacol Biopharm. 1976 Jun;13(4):235–245. [PubMed] [Google Scholar]
- Leber H. W., Harders A., Schütterle G. Untersuchungen zum einfluss der Urämie auf die Metabolisierung von Phenylbutazone und Aminophenazon beim Menschen. Klin Wochenschr. 1972 Dec 1;50(23):1092–1096. doi: 10.1007/BF01486853. [DOI] [PubMed] [Google Scholar]
- Niwa H., Hikichi N., Sasaki H. [Studies on metabolite of aminopyrine and its metabolic fate (author's transl)]. Yakugaku Zasshi. 1975 Sep;95(9):1050–1057. doi: 10.1248/yakushi1947.95.9_1050. [DOI] [PubMed] [Google Scholar]
- Nogami H., Hanano M., Awazu S., Imaoka K. [Studies on absorption and excretion of drugs. XVI. Determination of sulpyrin and its metabolites in the rat urine]. Yakugaku Zasshi. 1970 Mar;90(3):378–383. doi: 10.1248/yakushi1947.90.3_378. [DOI] [PubMed] [Google Scholar]
- PECHTOLD F. ZUR KENNTNIS DES ABBAUES VON DIMETHYLAMINOPHENYLDIMETHYLPYRAZOLON IM ORGANISMUS. Arzneimittelforschung. 1964 Aug;14:972–974. [PubMed] [Google Scholar]
- Preuss F. R., Voigt K. M. Uber die Vorstufen und die Bildung der Methylrubazonsäure nach Einahme von Amidopyrin. Zugleich eine Ubersicht zum Abbau des Dimethylamino-phenyl-dimethyl-pyrazolons. Arzneimittelforschung. 1965 Jul;15(7):741–747. [PubMed] [Google Scholar]
- Roots I., Saalfrank K., Hildebrandt A. G. Comparison of methods to study enzyme induction in man. Adv Exp Med Biol. 1975;58(00):485–502. doi: 10.1007/978-1-4615-9026-2_33. [DOI] [PubMed] [Google Scholar]
- SCHUEPPEL R., SOEHRING K. QUALITATIVE UNTERSUCHUNGEN UEBER DEN AMIDOPYRIN-STOFFWECHSEL BEIM MENSCHEN. Pharm Acta Helv. 1965 Feb;40:105–124. [PubMed] [Google Scholar]
- Shimeno H., Yoshimura H. Possible implication of a aldehyde metabolite in aminopyrine allergy. Xenobiotica. 1972 Sep;2(5):461–468. doi: 10.3109/00498257209111074. [DOI] [PubMed] [Google Scholar]
- Sioufi A., Marfil F. Gas chromatographic determination of phenazone derivatives in human plasma. II. Propyphenazone. J Chromatogr. 1978 Nov 1;146(3):508–517. doi: 10.1016/s0378-4347(00)81213-x. [DOI] [PubMed] [Google Scholar]
- Tateishi M., Shimizu H. The metabolism of isopropylantipyrine in the rat and man. Xenobiotica. 1976 Apr;6(4):207–215. doi: 10.3109/00498257609151631. [DOI] [PubMed] [Google Scholar]
- VON BLUMRODER W. O. Erfahrungen nit Raupentin bei essentieller Hypertonie. Medizinische. 1959 Mar 14;4(11):473–474. [PubMed] [Google Scholar]
- Vesell E. S., Passananti G. T., Glenwright P. A., Dvorchik B. H. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine. Clin Pharmacol Ther. 1975 Sep;18(3):259–272. doi: 10.1002/cpt1975183259. [DOI] [PubMed] [Google Scholar]
- Weiss R., Brauer J., Goertz U., Petry R. Vergleichende Untersuchungen zur Frage der Absorption und Metabolisierung des Pyrazolonderivates Metamizol nach oraler und intramuskulärer Gabe beim Menschen. Arzneimittelforschung. 1974 Mar;24(3):345–348. [PubMed] [Google Scholar]
- Windorfer A., Jr, Müller G., Stehr C. Veränderungen des Aminophenazon-Metabolismus bei akuter Hepatitis im Kindesalter. Dtsch Med Wochenschr. 1977 Oct 14;102(41):1460–1464. doi: 10.1055/s-0028-1105522. [DOI] [PubMed] [Google Scholar]
- Yoshimura H., Shimeno H., Tsukamoto H. [Metabolism of drugs. LXXI. The study on aminopyrine metabolism]. Yakugaku Zasshi. 1970 Nov;90(11):1406–1411. doi: 10.1248/yakushi1947.90.11_1406. [DOI] [PubMed] [Google Scholar]
- Zietz E., Eichelbaum M., Dengler H. J., Spiteller G. Zum Metabolismus von Antipyrin (Phenazon) beim Menschen. Arzneimittelforschung. 1978;28(2):315–319. [PubMed] [Google Scholar]